INZY

Inozyme Pharma, Inc. [INZY] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

INZY Stock Summary

Top 10 Correlated ETFs

INZY


Top 10 Correlated Stocks

INZY


In the News

08:30 29 Mar 2024 INZY

Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024

- Company to host conference call and webcast featuring key opinion leaders on Monday, April 8, 2024 at 8:00 a.m. ET - BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will host a conference call and webcast on Monday, April 8, 2024 at 8:00 a.m.

08:30 29 Mar 2024 INZY

Inozyme Pharma to Participate in Upcoming Investor Conferences

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that Douglas A. Treco, Ph.D., the Company's chief executive officer and chairman of the board, will participate at the following investor conferences:

01:33 29 Mar 2024 INZY

Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade

Inozyme Pharma, Inc. (INZY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

08:30 29 Mar 2024 INZY

Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company's chief executive officer and chairman of the board, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, from 12:00-12:30pm ET.

10:54 29 Mar 2024 INZY

3 Penny Stocks To Buy According To Insiders In August 2023

Penny stocks are an interesting asset class when it comes to making money in the stock market. Their inherent risk/reward makeup lends to heavy speculation and a thirst for significant gains.

07:30 29 Mar 2024 INZY

Inozyme Pharma to Present at the Jefferies Healthcare Conference

BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company's chief executive officer and chairman of the board, will present at the Jefferies Healthcare Conference on Friday, June 9, 2023, from 9:30-9:55 a.m. ET.

08:30 29 Mar 2024 INZY

Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)

BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Yves Sabbagh, Ph.D., the company's senior vice president and chief scientific officer, will present recently announced preliminary data from the ongoing Phase 1/2 clinical trial of INZ-701 in patients with ENPP1 Deficiency in an oral presentation on Monday, April 17 at the European Calcified Tissue Society Congress (ECTS) in Liverpool, UK.

10:25 29 Mar 2024 INZY

Pivotal bioVenture Partners Fund I Now Owns 7.4% of Inozyme Pharma

Fintel reports that Pivotal bioVenture Partners Fund I has filed a 13D/A form with the SEC disclosing ownership of 3.21MM shares of Inozyme Pharma Inc (INZY).

04:51 29 Mar 2024 INZY

Inozyme Pharma: Rare Disease Player Merits Revaluation Higher After POC Data

Shares are down 58% over the past year. Enzyme replacement therapy is an attractive area of drug development with less risk than more exotic modalities like gene therapy.

06:00 29 Mar 2024 INZY

Choosing Penny Stocks for Short Term Trading; 3 Tips

Use these tips for trading penny stocks in the short term The post Choosing Penny Stocks for Short Term Trading; 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

INZY Financial details

Company Rating
Neutral
Market Cap
358.28M
Income
-70M
Revenue
0
Book val./share
2.27
Cash/share
3.05
Dividend
-
Dividend %
-
Employees
59
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-4.02
Forward P/E
-4.79
PEG
1.88
P/S
-
P/B
1.65
P/C
2.48
P/FCF
-4.32
Quick Ratio
15.68
Current Ratio
16.36
Debt / Equity
0.33
LT Debt / Equity
0.32
-
-
EPS (TTM)
-1.36
EPS next Y
-1.58
EPS next Q
-0.35
EPS this Y
-20.81%
EPS next Y
15.86%
EPS next 5Y
-101.47%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
20.69%
-
-
-
-
SMA20
16.67%
SMA50
75%
SMA100
133.33%
Inst Own
68%
Inst Trans
0.87%
ROA
-32%
ROE
-54%
ROC
-0.37%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
61.77M
Shs Float
41.16M
-
-
-
-
Target Price
-
52W Range
2.689-7.33
52W High
+8.14%
52W Low
+278.5%
RSI
72
Rel Volume
2.2
Avg Volume
490.41K
Volume
1.08M
Perf Week
28.09%
Perf Month
32.57%
Perf Quarter
96.11%
Perf Half Y
75.64%
-
-
-
-
Beta
1.337
-
-
Volatility
0.7%, 0.54%
Prev Close
2.44%
Price
7.57
Change
9.39%

INZY Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-1.23-5.06-2.39-1.73-1.37
Operating cash flow per share
-1.24-3.26-2.04-1.53-1.36
Free cash flow per share
-1.25-3.31-2.06-1.54-1.37
Cash per share
3.1125.334.753.393.64
Book value per share
-2.1914.334.643.142.71
Tangible book value per share
-2.1914.334.643.142.71
Share holders equity per share
-2.1914.334.643.142.71
Interest debt per share
00.090.140.140.95
Market cap
265.89M227.79M160.67M39.65M220.83M
Enterprise value
234.29M69.18M140.72M13.51M232.84M
P/E ratio
-14.28-4.08-2.85-0.61-3.1
Price to sales ratio
00000
POCF ratio
-14.14-6.33-3.34-0.69-3.12
PFCF ratio
-14.03-6.23-3.31-0.68-3.11
P/B Ratio
-81.441.470.331.57
PTB ratio
-81.441.470.331.57
EV to sales
00000
Enterprise value over EBITDA
-11.31-1.21-2.51-0.2-3.13
EV to operating cash flow
-12.46-1.92-2.92-0.23-3.29
EV to free cash flow
-12.36-1.89-2.9-0.23-3.28
Earnings yield
-0.07-0.25-0.35-1.65-0.32
Free cash flow yield
-0.07-0.16-0.3-1.47-0.32
Debt to equity
00.010.030.060.33
Debt to assets
00.010.030.050.23
Net debt to EBITDA
1.532.780.360.38-0.16
Current ratio
14.6715.149.928.9313.36
Interest coverage
00042.55-22.7
Income quality
0.950.640.850.860.99
Dividend Yield
0000.10.18
Payout ratio
000-0.06-0.57
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.010.020.010.010
Capex to revenue
00000
Capex to depreciation
-1.67-2.62-0.59-0.55-0.23
Stock based compensation to revenue
00000
Graham number
7.7840.3815.8111.079.15
ROIC
0.59-0.35-0.49-0.52-0.4
Return on tangible assets
-0.39-0.33-0.46-0.47-0.35
Graham Net
-2.2423.764.142.842.48
Working capital
44.22M141.01M103.71M116.68M181.56M
Tangible asset value
-33.22M158.1M109.27M118.39M140.48M
Net current asset value
-33.7M139.72M101.07M110.59M135.88M
Invested capital
00.010.030.060.33
Average receivables
67.5K129.5K108.5K88.5K250K
Average payables
942.5K1.99M2.73M2.47M1.86M
Average inventory
0-6.18M-6.21M-88.5K-57.5K
Days sales outstanding
00000
Days payables outstanding
3.96K5.16K830.62788.92328.89
Days of inventory on hand
0-20.78K-21.51-35.660
Receivables turnover
00000
Payables turnover
0.090.070.440.461.11
Inventory turnover
0-0.02-16.97-10.230
ROE
0.56-0.35-0.52-0.55-0.51
Capex per share
-0.01-0.05-0.02-0.01-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.46-0.37-0.35-0.29-0.35
Operating cash flow per share
-0.38-0.41-0.35-0.33-0.3
Free cash flow per share
-0.38-0.41-0.35-0.33-0.3
Cash per share
3.392.993.133.393.05
Book value per share
3.142.362.352.822.27
Tangible book value per share
3.142.362.352.822.27
Share holders equity per share
3.142.362.352.822.27
Interest debt per share
0.150.580.760.60.79
Market cap
39.65M250.52M249.87M238.39M263.13M
Enterprise value
13.51M228.16M243.14M225.59M275.14M
P/E ratio
-0.56-3.86-4.01-3.58-3.05
Price to sales ratio
00000
POCF ratio
-2.75-14.1-16.07-12.63-14.23
PFCF ratio
-2.74-13.96-16.06-12.63-14.15
P/B Ratio
0.332.422.371.491.87
PTB ratio
0.332.422.371.491.87
EV to sales
00000
Enterprise value over EBITDA
-0.7-12.42-15.02-12.48-12.23
EV to operating cash flow
-0.94-12.84-15.64-11.96-14.88
EV to free cash flow
-0.94-12.71-15.63-11.95-14.8
Earnings yield
-0.44-0.06-0.06-0.07-0.08
Free cash flow yield
-0.36-0.07-0.06-0.08-0.07
Debt to equity
0.060.260.320.210.33
Debt to assets
0.050.190.230.170.23
Net debt to EBITDA
1.351.220.420.71-0.53
Current ratio
8.9310.6611.8916.3613.36
Interest coverage
19.7515.6700-6.84
Income quality
0.781.0211.130.86
Dividend Yield
00.08000
Payout ratio
0-1.24000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00.01000.01
Capex to revenue
00000
Capex to depreciation
-0.23-0.85-0.05-0.03-0.34
Stock based compensation to revenue
00000
Graham number
5.734.444.294.314.22
ROIC
-0.14-0.13-0.11-0.09-0.12
Return on tangible assets
-0.13-0.11-0.1-0.08-0.11
Graham Net
2.842.122.122.592.08
Working capital
116.68M121.57M131.51M188.58M181.56M
Tangible asset value
118.39M103.35M105.59M160.21M140.48M
Net current asset value
110.59M95.7M98.25M155.37M135.88M
Invested capital
0.060.260.320.210.33
Average receivables
105.5K57.5K00192.5K
Average payables
1.97M2.18M1.91M2.01M1.59M
Average inventory
-57.5K-57.5K000
Days sales outstanding
00000
Days payables outstanding
733.85504.17547.61542.16342.94
Days of inventory on hand
-33.170000
Receivables turnover
00000
Payables turnover
0.120.180.160.170.26
Inventory turnover
-2.710000
ROE
-0.15-0.16-0.15-0.1-0.15
Capex per share
00000

INZY Frequently Asked Questions

What is Inozyme Pharma, Inc. stock symbol ?

Inozyme Pharma, Inc. is a US stock , located in Boston of Ma and trading under the symbol INZY

What is Inozyme Pharma, Inc. stock quote today ?

Inozyme Pharma, Inc. stock price is $7.57 today.

Is Inozyme Pharma, Inc. stock public?

Yes, Inozyme Pharma, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap